CO4770964A1 - Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos - Google Patents
Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestosInfo
- Publication number
- CO4770964A1 CO4770964A1 CO96058504A CO96058504A CO4770964A1 CO 4770964 A1 CO4770964 A1 CO 4770964A1 CO 96058504 A CO96058504 A CO 96058504A CO 96058504 A CO96058504 A CO 96058504A CO 4770964 A1 CO4770964 A1 CO 4770964A1
- Authority
- CO
- Colombia
- Prior art keywords
- preparation
- compounds
- procedure
- amino acid
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA INVENCION SE REFIERE A NUEVOS DERIVADOS DE AMI NOACIDOS DE LA FORMULA GENERAL I Y SUS SALES FARMA CEUTICAMENTE ACEPTABLES, EN DONDE R1,A1,A2,R2,R1 Y R11 POSEEN LOS SIGNIFICADOS INDICADOS EN LA MEMO RIA DESCRIPTIVA, ASI COMO SU PREPARACION Y EMPLEO. LOS NUEVOS COMPUESTOS SON VALIOSOS ANTAGONISTAS DE NEUROQUININA *TAQUININA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19541283A DE19541283A1 (de) | 1995-11-06 | 1995-11-06 | Neue Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
Publications (1)
Publication Number | Publication Date |
---|---|
CO4770964A1 true CO4770964A1 (es) | 1999-04-30 |
Family
ID=7776728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO96058504A CO4770964A1 (es) | 1995-11-06 | 1996-11-06 | Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos |
Country Status (12)
Country | Link |
---|---|
US (1) | US6232468B1 (es) |
EP (1) | EP0871653B1 (es) |
JP (1) | JP3912798B2 (es) |
AR (1) | AR004291A1 (es) |
AT (1) | ATE235507T1 (es) |
AU (1) | AU7562296A (es) |
CA (1) | CA2234610C (es) |
CO (1) | CO4770964A1 (es) |
DE (2) | DE19541283A1 (es) |
MX (1) | MX9803004A (es) |
WO (1) | WO1997017362A1 (es) |
ZA (1) | ZA969248B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1307809B1 (it) | 1999-10-21 | 2001-11-19 | Menarini Ricerche Spa | Composti monociclici basici ad azione nk-2 antagonista, processi difabbricazione e formulazioni che li contengono. |
CN101119969B (zh) | 2004-07-15 | 2014-04-09 | 阿尔巴尼分子研究公司 | 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用 |
GB2418426A (en) * | 2004-08-18 | 2006-03-29 | Univ Cambridge Tech | Alpha-(acylamino)-bicyclolactam derivatives for treatment of inflammatory disorders |
GB2418427A (en) * | 2004-09-02 | 2006-03-29 | Univ Cambridge Tech | Ligands for G-protein coupled receptors |
WO2006123182A2 (en) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Cyclohexyl sulphones for treatment of cancer |
JP5258561B2 (ja) | 2005-07-15 | 2013-08-07 | アルバニー モレキュラー リサーチ, インコーポレイテッド | アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用 |
EP1940842B1 (en) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
SI2805945T1 (sl) | 2007-01-10 | 2019-09-30 | Msd Italia S.R.L. | Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP) |
CN101641099A (zh) | 2007-01-24 | 2010-02-03 | 葛兰素集团有限公司 | 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物 |
EP2145884B1 (en) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledione derivative |
WO2009002495A1 (en) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
WO2009111354A2 (en) | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
BRPI1008008A2 (pt) * | 2009-02-24 | 2016-02-23 | Novartis Ag | usos de antagonistas do receptor de nk |
WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
ES2662072T3 (es) | 2009-05-12 | 2018-04-05 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma |
ES2528404T3 (es) | 2009-05-12 | 2015-02-10 | Bristol-Myers Squibb Company | Formas cristalinas de (S)-7-([1,2,4]triazol[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y sus usos |
ES2446971T3 (es) | 2009-05-12 | 2014-03-11 | Albany Molecular Research, Inc. | Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso |
WO2011046771A1 (en) | 2009-10-14 | 2011-04-21 | Schering Corporation | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
WO2012018754A2 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP3587574B1 (en) | 2010-08-17 | 2022-03-16 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
EP2632472B1 (en) | 2010-10-29 | 2017-12-13 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
WO2012145471A1 (en) | 2011-04-21 | 2012-10-26 | Merck Sharp & Dohme Corp. | Insulin-like growth factor-1 receptor inhibitors |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
EP3919620A1 (en) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
US9233979B2 (en) | 2012-09-28 | 2016-01-12 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
PL2925888T3 (pl) | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme Corp. | Kompozycje i sposoby do stosowania w leczeniu nowotworów |
CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
US11993602B2 (en) | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5164372A (en) * | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
GB9113219D0 (en) * | 1991-06-19 | 1991-08-07 | Fujisawa Pharmaceutical Co | Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same |
DE59309867D1 (de) | 1992-09-03 | 1999-12-16 | Boehringer Ingelheim Pharma | Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen |
DE4243496A1 (de) * | 1992-09-03 | 1994-03-10 | Boehringer Ingelheim Kg | Neue Dipeptidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
DE4326465A1 (de) | 1993-01-20 | 1995-02-09 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE4445939A1 (de) * | 1994-05-07 | 1995-11-09 | Boehringer Ingelheim Kg | Neue Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen (II) |
EE9600186A (et) | 1994-05-07 | 1997-08-15 | Boehringer Ingelheim Kg | Neurokiniini (tahhüülkiniini) antagonistid |
-
1995
- 1995-11-06 DE DE19541283A patent/DE19541283A1/de not_active Ceased
-
1996
- 1996-11-04 EP EP96938049A patent/EP0871653B1/de not_active Expired - Lifetime
- 1996-11-04 WO PCT/EP1996/004771 patent/WO1997017362A1/de active IP Right Grant
- 1996-11-04 DE DE59610280T patent/DE59610280D1/de not_active Expired - Lifetime
- 1996-11-04 AT AT96938049T patent/ATE235507T1/de not_active IP Right Cessation
- 1996-11-04 AU AU75622/96A patent/AU7562296A/en not_active Abandoned
- 1996-11-04 CA CA002234610A patent/CA2234610C/en not_active Expired - Fee Related
- 1996-11-04 ZA ZA969248A patent/ZA969248B/xx unknown
- 1996-11-04 JP JP51782297A patent/JP3912798B2/ja not_active Expired - Fee Related
- 1996-11-06 CO CO96058504A patent/CO4770964A1/es unknown
- 1996-11-06 AR ARP960105070A patent/AR004291A1/es unknown
-
1998
- 1998-04-16 MX MX9803004A patent/MX9803004A/es unknown
-
1999
- 1999-12-01 US US09/451,894 patent/US6232468B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0871653B1 (de) | 2003-03-26 |
JP2000501382A (ja) | 2000-02-08 |
EP0871653A1 (de) | 1998-10-21 |
AR004291A1 (es) | 1998-11-04 |
AU7562296A (en) | 1997-05-29 |
MX9803004A (es) | 1998-09-30 |
DE19541283A1 (de) | 1997-05-07 |
ATE235507T1 (de) | 2003-04-15 |
DE59610280D1 (de) | 2003-04-30 |
US6232468B1 (en) | 2001-05-15 |
JP3912798B2 (ja) | 2007-05-09 |
WO1997017362A1 (de) | 1997-05-15 |
CA2234610A1 (en) | 1997-05-15 |
ZA969248B (en) | 1997-05-06 |
CA2234610C (en) | 2007-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO4770964A1 (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos | |
MX9305379A (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene. | |
AR009938A1 (es) | Nuevos derivados de arilglicinamida, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos | |
AR004516A1 (es) | Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen | |
UY27109A1 (es) | Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b | |
BG100946A (en) | New amino acid derivatives, method for their preparation and pharmaceutical compositions containing them | |
ES2194937T3 (es) | Compuestos ciclicos, su produccion y uso como antagonistas de los receptores de taquiquinina. | |
TR199801594A2 (xx) | CCR-3 resept�r antagonistleri. | |
TR200001973T2 (tr) | 11 ß-halojen-7alfa-ile ikame edilmiş-estratrienler, bu 11ß-halojen-7alfa-ile ikame edilmiş-estratrienleri içeren farmasötik terkiplerin üretimi için yöntem ve ilaç üretiminde kullanımları. | |
TR200001079T2 (tr) | Bisiklik kinaz inhibitörleri. | |
AR077414A2 (es) | Compuestos de piperazina como antagonistas de taquinina sus sales y solvatos composiciones farmaceuticas que lo contienen su uso y procesos para su preparacion | |
ES2159738T3 (es) | Derivados de benzamida y su uso como antagonistas de vasopresina. | |
PE20040946A1 (es) | Compuestos de pirazolotriazina como ligandos del receptor cannabinoide | |
ES2058527T3 (es) | Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen. | |
AR002268A1 (es) | Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas. | |
AR035153A1 (es) | Derivados de carboxamidas y cetonas de dihidrobenzodioxina | |
PT824530E (pt) | Derivados de arilglicinamida, processos para a sua producao e preparacoes farmaceuticas contendo estes compostos | |
AR015712A1 (es) | Derivados de 3,4-dihidro-tieno[2,3-d]pirimidina-3-sustituidos y su uso para la preparacion de composiciones farmaceuticas | |
AR006119A1 (es) | Compuestos de quinoxalinadionas uso de los mismos para la fabricacion de un medicamento, compuestos de quinoxalinas para producirlos y procedimiento parala preparacion de los mismos | |
DE69401716D1 (de) | Imidazo [1,2-a] pyrasin-4-on-derivate welche als ampa und nmda receptor antagonisten dienen | |
AR021843A1 (es) | Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion. | |
AR028743A1 (es) | DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA | |
ES2158099T3 (es) | Derivados de imidazo(1,2-a)indeno(1,2-e)pirazina-4-ona y composiciones farmaceuticas que los contienen. | |
PA8486701A1 (es) | Antagonistas de 5ht1 para terapia antidepresiva | |
BG106847A (en) | Substituted piperazine derivatives as mtp inhibitors |